Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer

The application featured clinical data for two dosing regimens: 400mg BID fed (n=57) and 600mg BID fasted (n=52). Credit: Joeahead / Shutterstock.com.



  • Relay Therapeutic FDA